ILMN

Illumina, Inc.

$262.54

-2.01% 2026-10-16

Health CareS&P 500

1M 3M 6M 1Y 2Y

ILMNSPY

-5.6%

+14.7%

+40.7%

+95.2%

YTD

+100.2%

+173.7%

Grades vs sector

Momentum

99th pct in sector

A+

12-1 return: +121.5%
Percentile within its GICS sector across the S&P 1500.

Growth

54th pct in sector

C+

Revenue growth (YoY): +9.4%
Percentile within its GICS sector across the S&P 1500.

Value

9th pct in sector

D-

Forward E/P: 2.3% · EBITDA/EV: 2.8%
Percentile within its GICS sector across the S&P 1500.

Profitability

83rd pct in sector

A-

Profit margin: +18.3% · Return on equity: +32.3%
Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

rank 18 of 499 · 12-1 momentum % 124.9

Quality Growth

rank 91 of 360 · Composite (0-1) 0.6

Momentum Blend

not in the current book

Key stats

Market cap$39.6B

P/E (trailing)49.0

P/E (forward)42.9

52-week range94.00 – 309.35

Revenue growth (YoY, latest qtr)+9.4%

Dividend yield0.00%

Analyst consensusBuy (20)

Mean price target$241.05 (-8%)

Valuation & fundamentals

Bottom line

Looks expensive

Model read-out from the numbers below, not advice. Score -3 (DCF counts double).

▼DCF (base case)below the price by 71%

▼Forward P/E vs sector42.9x vs median 17.6x

▲Piotroski F-score8/9

▲Net debt / EBITDA0.0x

▼Analyst target-8% (20 analysts)

Discounted cash flow

Bear

$52

-80%

growth -1% · disc. 12.3% · term. 2.0%

Base

$77

-71%

growth 4% · disc. 11.3% · term. 2.5%

Bull

$107

-59%

growth 7% · disc. 10.3% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 21% a year for 10 years.

Implied

+21%/yr

FCF, last 3 yrs

+106%/yr

FCF, last 5 yrs

+1%/yr

Revenue, last 3 yrs

-2%/yr

Revenue, last 5 yrs

+6%/yr

Same inputs as the DCF above: trailing free cash flow 0.9B, 11.3% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-28). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.42 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 80th pct

49.0×
pricier

Forward P/E

sector median 17.6× · 91st pct

42.9×
pricier

EV / EBITDA

sector median 15.8× · 89th pct

34.4×
pricier

Price / sales

sector median 3.1× · 85th pct

8.8×
pricier

Price / book

sector median 3.5× · 91st pct

14.0×
pricier

FCF yield

sector median 4.1% · 26th pct

2.3%
pricier

Forward EPS $6.13 vs trailing $5.36 (+14% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$1.0B

as of 2026-06-28

vs a year ago

+16%

YoY

× TTM revenue

0.22×

coverage

24-09

24-12

25-03

25-06

25-09

25-12

26-03

26-06

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

66.4%

Operating margin

19.6%

FCF margin

20.7%

Net margin

18.3%

Return on equity

29.0%

Return on invested capital

25.2%

Net debt / EBITDA

0.0×

Current ratio

1.8×

Interest cover

9.0×

Cash conversion (OCF/NI)

1.3×

Piotroski F-score 8/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✓ Gross margin improved✗ Asset turnover improved

Analysts

Mean target

$241

-8%

Analysts

Buy

Range

–

low – high

Annual history

FY	Revenue	Net income	Free cash flow
2025	$4.3B	$850.0M	$931.0M
2024	$4.4B	$-1.2B	$709.0M
2023	$4.5B	$-1.2B	$283.0M
2023	$4.6B	$-4.4B	$106.0M
2022	$4.5B	$762.0M	$337.0M
2021	$3.2B	$656.0M	$891.0M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -1.8%.

Earnings

Next report: 2026-10-29 · after close · EPS est 1.36

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-30	1.23	1.31	+6.8%
2026-04-30	1.05	1.15	+9.0%
2026-02-05	1.23	1.35	+9.7%
2025-10-30	1.17	1.34	+14.7%
2025-07-31	1.01	1.19	+17.7%
2025-05-08	0.94	0.97	+3.3%
2025-02-06	0.92	0.86	-6.8%
2024-11-04	0.88	1.14	+29.0%

Quarterly revenue

Quarter	Revenue	YoY
2026-03-31	$1.1B	+4.8%
2025-12-31	$1.2B	–
2025-09-30	$1.1B	–
2025-06-30	$1.1B	–
2025-03-31	$1.0B	–

Analyst actions

TD Cowen

2026-10-13 · main

Hold → Hold
PT $270

Barclays

2026-10-07 · main

Underweight → Underweight
PT $200

RBC Capital

2026-10-05 · main

Outperform → Outperform
PT $310

Guggenheim

2026-10-01 · main

Buy → Buy
PT $305

Leerink Partners

2026-09-29 · main

Outperform → Outperform
PT $300

Piper Sandler

2026-09-28 · main

Overweight → Overweight
PT $305

Insider trades

Meister Keith A.

Director · 2026-09-04

SELL
$1.6M

Meister Keith A.

Director · 2026-09-04

SELL
$22.0M

Meister Keith A.

Director · 2026-09-04

SELL
$2.5M

Meister Keith A.

Director · 2026-09-03

SELL
$1.8M

Meister Keith A.

Director · 2026-09-03

SELL
$2.9M

Meister Keith A.

Director · 2026-09-03

SELL
$3.1M

Meister Keith A.

Director · 2026-09-03

SELL
$2.1M

Meister Keith A.

Director · 2026-09-03

SELL
$3.0M

Meister Keith A.

Director · 2026-09-03

SELL
$1.5M

Meister Keith A.

Director · 2026-09-03

SELL
$2.2M

Meister Keith A.

Director · 2026-09-02

SELL
$12.3M

Meister Keith A.

Director · 2026-09-02

SELL
$2.3M

News

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

Zacks · Oct 16

Immuno-Oncology Diagnostics Market to Reach $11.1B by 2030 as Checkpoint Inhibitor and Cell Therapy Pipelines Drive Demand for Companion Tests

GlobeNewswire · Oct 16

Global Proteomic Biomarker Analytics Market: Five-Year Forecast by Application, Technology, Product, and End User | Double-Digit Growth Boosts Cancer Diagnostics and Drug Discovery

GlobeNewswire · Oct 16

GTT Group Founder Michael Lubitz Joining Expert Panel at IAM Patent Transactions 2026 in San Diego

PR Newswire · Oct 15

Invesco S&P 500 Equal Weight ETF (RSP) Adds Moderna and Everpure on Tuesday

GuruFocus.com · Oct 15

Iambic, an AI drug discovery specialist, banks $150M in an IPO

BioPharma Dive · Oct 14

Illumina Debuts BioInsight Platform, Expands AI Tools for Genomic Research

MT Newswires · Oct 14

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

PR Newswire · Oct 14

Stats refreshed 2026-10-18 22:39:29 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status